How many drugs is Alexion?

Alexion Pharmaceuticals, Inc. manufactures, markets and/or distributes more than 4 pharmaceuticals in the United States.

Who owns Alexion Pharmaceuticals?

AstraZeneca
Alexion Pharmaceuticals/Parent Organizations

July 21 marks the beginning of Alexion's next chapter, with the exciting news that we have been acquired by AstraZeneca, a global science-led biopharmaceutical company. This development also marks the creation of Alexion, the AstraZeneca Rare Disease.

How much is Alexion worth?

With costs that can reach $2 million a year, the drugs manufactured by Alexion are some of the most expensive drugs worldwide…Alexion Pharmaceuticals.

What happened to Alexion Pharmaceuticals?

AstraZeneca today completed the acquisition of Alexion Pharmaceuticals, Inc. (Alexion). Our ongoing R&D investment in oncology, cardiovascular and renal, and respiratory and immunology has driven AstraZeneca's transformation, and now we are adding rare diseases where there are fewer approved treatment options."

Did AstraZeneca buy Alexion?

Dive Brief: AstraZeneca expects to complete its $39 billion acquisition of Alexion on July 21 after receiving the final regulatory approval it needed from the UK Competition and Markets Authority.

Is Alexion a buy?

Alexion Pharmaceuticals has received a consensus rating of Hold. The company's average rating score is 2.22 based on 4 buy ratings, 14 hold ratings and no sell ratings.

Who are Alexion Pharmaceuticals' competitors?

Alexion Pharmaceuticals' major competitors include Regeneron Pharmaceuticals, Abiogen Pharma, Heron Therapeutics and Pharming Group.

Who is the CEO of Alexion?

Ludwig N. Hantson (March 2017–)
Alexion Pharmaceuticals/CEO

No, AstraZeneca stock is not a buy right now.

Alexion Pharmaceuticals has received a consensus rating of Hold. The company's average rating score is 2.18 based on 3 buy ratings, 14 hold ratings and no sell ratings.

Is Amgen a buy or sell?

Amgen has received a consensus rating of Hold. The company's average rating score is 2.45 based on 12 buy ratings, 8 hold ratings and 2 sell ratings.

Is Alxn underrated?

PE vs. industry: ALXN is poorly valued based on its PE ratio (58.8x) compared to the US biotech industry average (28x). PE vs. market: ALXN is poorly valued based on its PE ratio (58.8x) compared to the US market (18.7x).

What kind of company is Alexion Pharmaceuticals?

Alexion is a global biopharmaceutical company focused on developing and delivering life-changing treatments for patients with devastating and rare diseases.

When did AstraZeneca buy out Alexion Pharmaceuticals?

In December 2020, AstraZeneca announced that it would acquire the company; at the time of the announcement, the deal was worth $39 billion. Following completion of the merger, Alexion shareholders will own 15% of the combined company.

Who is buying Alexion for $39 billion?

Alexion (ALXN) to be acquired by AstraZeneca for $39 billion

When did Alexion Pharmaceuticals move to Cheshire CT?

In 2000, Alexion moved its headquarters from New Haven to Cheshire, Connecticut. Alexion moved back to New Haven following the completion of New Haven's Downtown Crossing project in December 2015.